\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes MSCAAs part of their 30th anniversary in 2026, the Marie Skłodowska-Curie Actions (MSCA) are teaming up with Frontiers for Young Minds (FYM) to publish a special collection on “Young researchers who will change the world”. FYM is a non-profit linked to the scientific journal Frontiers. Its goal is to make cutting-edge science discoveries available to younger audiences.
The MSCA is looking for 12 excellent abstracts (between 200 and 300 words) from young MSCA fellows that will later be turned into 12 engaging short papers (1500 words) with the help of young students between the ages of 8 to 15. This call is for young MSCA fellows (PhD candidates, postdoctoral researchers or research and innovation staff). The submissions deadline is 31 July 2025, 12.00, CEST.
Find more information about the call, evaluation criteria, previous FYM articles and application form in this news article on the MSCA website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
